ScottKnowlesPruittMD
General Surgery • Durham, NCSurgical Oncology (Other than Breast)
Associate Professor, Surgery, Duke University School of Medicine
Are you Dr. Pruitt?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 120 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
508 Fulton St
Durham Va Medical Center
Durham, NC 27705Phone+1 919-684-3942
Summary
- Dr. Scott Pruitt, MD is a general surgeon in Durham, North Carolina. He is currently licensed to practice medicine in North Carolina. He is affiliated with Durham Veterans Affairs Medical Center and is an Associate Professor at Duke University School of Medicine.
Education & Training
Duke University HospitalResidency, Surgery, 1987 - 1997
Columbia University Vagelos College of Physicians and SurgeonsClass of 1987
Certifications & Licensure
NC State Medical License 1997 - 2024- American Board of Surgery Surgery
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells Start of enrollment: 2008 Jan 01
- Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma Start of enrollment: 2010 Jan 01
Publications & Presentations
PubMed
- 1516 citationsEfficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.Aurélien Marabelle, Dung T. Le, Paolo A. Ascierto, Anna Maria Di Giacomo, Ana De Jesus-Acosta
Journal of Clinical Oncology. 2020-01-01 - 582 citationsEfficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study.Hyun Cheol Chung, Willeke Ros, Jean Pierre Delord, Ruth Perets, Antoine Italiano
Journal of Clinical Oncology. 2019-04-03 - 182 citationsThe effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenograftsScott K. Pruitt, Allan D. Kirk, R. Randal Bollinger, Henry C. Marsh, Bradley H. Collins
Transplantation. 1994-02-01
Press Mentions
Biden Administration Moves to Curtail Toxic ‘Forever Chemicals’August 26th, 2021- How Trump Damaged Science — and Why It Could Take Decades to RecoverOctober 5th, 2020
- Science, Sidelined by Trump Administration, Getting More Attention Because of COVID-19, University of Iowa Toxicologist SaysJuly 24th, 2020
- Join now to see all
Grant Support
- Immune Response To Breast Ductal Carcinoma In SituNational Institute Of Allergy And Infectious Diseases1997–1999
- Modulation Of Hyperacute Xenograft RejectionNational Institute Of Allergy And Infectious Diseases1992–1993
Professional Memberships
- Member
